Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 16 January 2026 - 21 January 2026

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s shares edged up 0.3% to close Tuesday at $1,041.29, then ticked 0.04% higher in after-hours action. The move followed news that the U.S. FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The change is slight, but it hits home as investors keep their eyes on Lilly’s pipeline beyond its blockbuster diabetes and obesity treatments. With the stock already factoring in perfect execution, even a hint of new growth potential makes an impact. The designation focuses on a hard-to-treat group of adults with
21 January 2026
·····
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

New York, Jan 20, 2026, 10:57 (EST) — Regular session Eli Lilly and Company shares (LLY) nudged up Tuesday following news of a U.S. FDA Breakthrough Therapy designation for its experimental ovarian-cancer drug. The stock traded around $1,040.38, up roughly 0.2%, after starting the session at $1,020 and dipping to a low of $1,019.66. Meanwhile, the SPDR S&P 500 ETF slipped about 1%. The label comes as investors push Lilly to demonstrate its growth extends beyond diabetes and obesity drugs like Mounjaro and Zepbound. When a stock is priced for consistent pipeline success, even a minor oncology update can move
20 January 2026
····
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

New York, Jan 19, 2026, 10:08 EST — Market closed Eli Lilly and Company shares drew attention heading into Tuesday’s U.S. session, following a Friday close in the green. Investors digested new developments in the obesity-drug sector, a key driver behind the drugmaker’s recent surge. The key question now: does the early appetite for new, easier-to-swallow weight-loss pills alter the game for established players, or just shuffle market share in a packed healthcare segment? For Lilly, minor tweaks in weekly prescription numbers can quickly sway sentiment, given that obesity and diabetes drugs are central to growth forecasts. U.S. stock markets
19 January 2026
····
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing.com) Investors are weighing whether Novo’s once-daily Wegovy pill is gaining traction in the U.S. as the obesity drug market shifts toward a consumer-driven, cash-pay model. IQVIA data revealed 3,071 retail prescriptions filled within the first four days after its Jan. 5 launch. Novo described the “early signs” as positive
18 January 2026
·······
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections. The setup is more delicate than it appears. Speeding up the timeline for a new oral
18 January 2026
······
Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

Merck stock price slips after FDA fast-track questions; what MRK investors watch next week

New York, January 17, 2026, 15:06 (EST) — Market closed Merck & Co (MRK.N) shares dropped 1.9% on Friday, ending the day at $108.83. That’s roughly 4% shy of their 52-week peak of $112.90 hit earlier this month. (Reuters) Investors start the week focused on a new FDA fast-track program targeting quick decisions—just one to two months—on a select group of drugs. Internal documents obtained by Reuters reveal the FDA has already postponed reviews for some medicines chosen for the Commissioner’s National Priority Voucher Program, which promises to shave four to six months off the usual “priority review” timeline. The
17 January 2026
·····
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week. (Reuters) U.S. markets are closed Monday for Martin Luther King Jr. Day, giving healthcare investors an extended break before action resumes Tuesday. The sector has fallen behind despite earnings season picking
17 January 2026
··········
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

New York, Jan 17, 2026, 10:03 ET — Market closed. Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication. The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to expand the market beyond injectable treatments. This matters because the company’s upcoming catalysts come in quick succession, and with the U.S. market reopening Tuesday after a holiday, the stock has limited time to absorb new developments before the next wave
17 January 2026
·····
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Copenhagen, Jan 17, 2026, 10:59 CET — Market closed. Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33. (Investing.com) This move is crucial as investors seek confirmation that Novo’s new Wegovy pill will maintain its first-to-market advantage amid growing competition, notably from Eli Lilly’s oral obesity drug. Novo described the “early signs” as positive but cautioned that it’s too soon to draw conclusions about trends for the daily pill. (Reuters) The initial figure was modest but clear:
17 January 2026
·······
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

NEW YORK, Jan 16, 2026, 21:08 EST — Market closed. Shares of Merck & Co (MRK.N) dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded. The drop came as investors digested a Reuters report revealing some drugmakers’ unease over the FDA Commissioner’s National Priority Voucher Program — a fast-track approval process launched in June that cuts review times to one or two months for select drugs. At the J.P. Morgan Healthcare Conference, executives and advisers warned the accelerated timeline might compromise safety
17 January 2026
·······
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

New York, January 16, 2026, 17:39 EST — After-hours Eli Lilly (LLY.N) shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch, a health policy professor at the University of Pennsylvania, noted the delay signals the agency remains cautious, essentially saying: “Hold on, we’re not actually sure this product should be allowed on the market.” (Reuters) Timing is crucial as Lilly vies
17 January 2026
·····
Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

Eli Lilly stock price edges higher as FDA timeline for obesity pill comes into focus

New York, Jan 16, 2026, 11:00 EST — Regular session Eli Lilly shares rose 0.3% to $1,036.46 on Friday morning, after touching as low as $1,019, as investors weighed an updated U.S. regulatory timeline for the company’s experimental obesity pill. (Reuters) The stock has become a proxy for how fast the next wave of weight-loss drugs can move from injections to pills — and whether demand holds up as insurers push back and more patients pay cash. That question is getting louder this week as early U.S. prescription data for Novo Nordisk’s newly launched Wegovy pill begins to circulate among
16 January 2026
···
1 2 3 4 5 6 … 13

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop